Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

NICE technology appraisals [TA127] Published date:

Natalizumab is recommended as a possible treatment for people with rapidly evolving severe relapsing-remitting multiple sclerosis.

Healthcare professionals should not stop prescribing natalizumab for people with other types of multiple sclerosis who were already taking it when the guidance was issued. These people should be able to carry on taking natalizumab until they and their doctor decide that it is the right time to stop.

Get involved